BREAKING NEWS: New drug approved by the FDA for Duchenne muscular dystrophy. Learn more about this new treatment option.

Medical Educational Resource

We're accelerating the delivery of treatments and cures.

Neuromuscular Clinical Trials: Boosting patient engagement and participation

Activity Snapshot

Activity Type: 
Release Date: 
Friday, May 13, 2022
Sponsor Information: 

This program is sponsored in part by an independent medical education grant from Mitsubishi Tanabe Pharma America, Inc.


Constantine Farmakidis, MD
Assistant Professor, Neurology
University of Kansas Medical Center
Activity Overview: 

This speaker slide set will provide an overview of the current clinical trial landscape in neuromuscular disease. Some topics included are barriers to participation, support for patient enrollment and increasing patient awareness and engagement.

Learning Objectives: 
  • Increase knowledge among healthcare providers about barriers to clinical trial (CT) participation and potential solutions
  • Understand barriers/facilitators to CT participation faced by patients and healthcare practitioners, including those specific to rare diseases
  • Access resources on finding and enrolling in CTs
  • Recognize solutions to overcome barriers to CT participation that have been used successfully in other fields (eg, oncology)
  • Understand the importance of informed consent and open communication with patients about CTs
  • Access resources to help more effectively discuss/evaluate CT options with patients
  • Adopt solutions in clinical practice to support CT participation